Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, the composition containing a mixed herbal extract of Genkwae Flos, Clematidis Radix, and Gastrodiae Rhizoma. In addition the present invention relates to a food composition or feedstuff composition for preventing or improving neurodegenerative diseases, wherein the composition contains the herbal extract.

Abstract: The present invention relates to a composition for preventing or alleviating metabolic bone diseases or menopausal symptoms, comprising a complex extract of Pueraria radix and Platycodon grandiflorum as an active ingredient. When the present invention is used, metabolic bone disease or menopausal symptoms can be effectively prevented or alleviated without side effects.

Abstract: Disclosed are a pharmaceutical composition for treatment of attention deficit hyperactivity disorder and a food composition for alleviation of attention deficit hyperactivity disorder, each of which contains as an active ingredient a mixture extract of Longan Arillus, Salviae Miltiorrhizae Radix, Gastrodiae Rhizoma, and Liriopis seu Ophiopogonis Tuber, wherein the compositions containing as an active ingredient a mixture extract of Longan Arillus, Salviae Miltiorrhizae Radix, Gastrodiae Rhizoma, and Liriopis seu Ophiopogonis Tuber of the present disclosure inhibits the hyperactivity of glutamate receptors, which is known to be a cause of attention deficit hyperactivity disorder, alleviates clinical symptoms (attention decrease and hyperactivity) of child patients, and shows an improvement effect in fMRI examination results, and thus can be advantageously used as a medicine for attention deficit hyperactivity disorder or a food for alleviation of attention deficit hyperactivity disorder.

Abstract: The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.

Abstract: The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal mobility disorders.

Abstract: The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.

Abstract: The present invention relates an agent comprising FGF2 (Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor (bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease (COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.

Abstract: The present invention relates an agent comprising FGF2 (Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor(bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease(COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.

Abstract: The present invention relates to pyrazolopyrimidinone derivatives of formula 1, their preparation method and pharmaceutical compositions containing the said derivatives. The compounds have efficacy on the treatment of impotence, one of male sexual dysfunctions with the side effects reduced.